Advanced Biomedical Research

Association of urinary transforming growth factor-β1 with the ureteropelvic junction obstruction

Authors

Department of Pediatrics, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: We aimed to compare the level of urinary transforming growth factor-beta 1 (TGF-β1 ) in children with ureteropelvic junction obstruction (UPJO) with the normal peers.
Materials and Methods: In this case-control study, we enrolled children with UPJO and matched normal peers. Sterile urine was collected from the subjects and urinary TGF-β1 was measured by ELISA method. Also, degree of the UPJO and the magnitude of the renal injury were assessed by ultrasonography and measuring glomerular filtration rate (GFR), respectively. Study variables were then compared between the study groups regarding the level of urinary TGF-β1 .
Results: A total of 25 children with UPJO (age = 7.4 ± 4.5 years; male = 16) were compared with 25 healthy peers (age = 6.8 ± 5.6 years; male = 16). Mean GFR in the UPJO and the control group were 112.4 ± 10.1 and 123.29 ± 4.4, respectively. Mean urinary TGF-β1 in the UPJO group was 87.1 ± 12.6 pg/ml vs 30.5 ± 14.5 pg/ml in the control group. The level of urinary TGF-β1 was significantly associated with the degree of TGF-β1 and patients with grade IV hydronephrosis had the highest level of urinary TGF-β (P = 0.0001).
Conclusion: Based on our findings, biomarkers such as TGF-β1 can successfully be used for confirming UPJO. However, further studies are needed to determine the proper cut point for diagnosis confirmation.

Keywords

1. Blyth B, Snyder HM, Duckett JW. Antenatal diagnosis and subsequent management of hydronephrosis. J Urol 1993;149:693-8.  Back to cited text no. 1
    
2. Sager C, Lopez JC, Duran V, Burek C, Perazzo E. Transforming growth factor-beta1 in congenital ureteropelvic junction obstruction: Diagnosis and follow-up. Int Braz J Urol 2009;35:315-23; discussion 23-5.  Back to cited text no. 2
    
3. Taha MA, Shokeir AA, Osman HG, Abd el-Aziz Ael A, Farahat SE. Diagnosis of ureteropelvic junction obstruction in children: Role of endothelin-1 in voided urine. Urology 2007;69:560-4; discussion 4-5.  Back to cited text no. 3
    
4. Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int 1996;49:1110-9.  Back to cited text no. 4
    
5. Seremetis GM, Maizels M. TGF-beta mRNA expression in the renal pelvis after experimental and clinical ureteropelvic junction obstruction. J Urol 1996;156:261-6.  Back to cited text no. 5
    
6. Yenh C, Wanl C, Chen SS, Huang CH. Expression of transforming growth factor-β1 and its receptors related to the ureteric fibrosis in a rat model of obstructive uropathy. J Urol 2000;163:1298-303.  Back to cited text no. 6
    
7. Basile DP. The transforming growth factor beta system in kidney disease and repair: Recent progress and future directions. Curr Opin Nephrol Hypertens 1999;8:21-30.  Back to cited text no. 7
[PUBMED]    
8. Gulmi F, Felsen D, Vaughan E. Pathophysiology of urinary tract obstruction. In: Walsh PC, Retik AT, Vaughan ED, Wein A, editors. Campbell's Urology. Vol. 1. Buenos Aires: Editorial Panamericana; 2004. p. 450-2.  Back to cited text no. 8
    
9. Chertin B, Pollack A, Koulikov D, Rabinowitz R, Hain D, Hadas-Halpren I, et al. Conservative treatment of ureteropelvic junction obstruction in children with antenatal diagnosis of hydronephrosis: Lessons learned after 16 years of follow-up. Eur Urol 2006;49:734-8.  Back to cited text no. 9
    
10. Misseri R, Meldrum KK. Mediators of fibrosis and apoptosis in obstructive uropathies. Curr Urol Rep 2005;6:140-5.  Back to cited text no. 10
    
11. Yang Y, Hou Y, Wang CL, Ji SJ. Renal expression of epidermal growth factor and transforming growth factor-beta 1 in children with congenital hydronephrosis. Urology 2006;67:817-21.  Back to cited text no. 11
    
12. Schnaper HW, Hayashida T, Poncelet AC. It's a Smad world: Regulation of TGF-β signaling in the kidney. J Am Soc Nephrol 2002;13:1126-8.  Back to cited text no. 12
[PUBMED]    
13. Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta 1. Am J Nephrol 2006;26:186-93.  Back to cited text no. 13
    
14. Honkanen E, Teppo AM, Törnroth T, Groop PH, Grönhagen-Riska C. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant 1997;12:2562-8.  Back to cited text no. 14
    
15. Shokeir AA. Role of urinary biomarkers in the diagnosis of congenital upper urinary tract obstruction. Indian J Urol 2008;24:313-9.  Back to cited text no. 15
[PUBMED]  Medknow Journal  
Advanced Biomedical Research
Volume 2014, May
May 2014
Pages 1-4